the panel 's recommendation of class iii for this category of device is consistent with the current class iii designation for these device types . if the fda accepts the panel 's determination and issues a final order classifying these devices in class iii , we will be required to file a pma application for impella 2.5. under the 515 program initiative , we will be permitted to continue to market our impella products pursuant to the 510 ( k ) clearance for a sufficient period of time to allow for the submission and review of pma applications relating to our impella products . we intend to submit a modular pma submission for impella by the end of fiscal 2014. a modular pma allows for a parallel submission of preclinical and manufacturing data for review while still preparing the clinical module . we are working with the fda to prepare this modular pma application for our impella products . in november 2011 , we announced symphony , a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics and potentially improving their quality of life . the device is designed with the primary goal of stabilizing the progression of heart failure and recovering or remodeling the heart . we are currently conducting first-in-human clinical trials of symphony outside the u.s. this product is not currently approved by the fda for sale in the u.s. on october 26 , 2012 , we were informed that the united states attorney 's office for the district of columbia is conducting an investigation that is focused on the company 's marketing and labeling of the impella 2.5. on october 31 , 2012 , we accepted service of a subpoena related to this investigation . the subpoena seeks documents related to the impella 2.5. we are in the process of responding and we intend to cooperate fully with the subpoena . on november 16 and 19 , 2012 , two purported class action complaints were filed against us and certain of our officers in the u.s. district court for the district of massachusetts by alleged purchasers of our common stock , on behalf of themselves and persons or entities that purchased or acquired our securities between august 5 , 2011 and october 31 , 2012. the complaints allege that the defendants violated the 30 federal securities laws in connection with disclosures related to the fda and the marketing and labeling of our impella 2.5 product and seek damages in an unspecified amount . the court has consolidated these complaints . a consolidated amended complaint was filed by the plaintiffs on may 20 , 2013. additionally , on february 4 , 2013 , an alleged holder of our common stock filed a derivative action on our behalf against each of our directors in the u.s. district court for the district of massachusetts . the complaint alleges that the directors breached their fiduciary duties to us and our stockholders in connection with disclosures related to the fda and the marketing and labeling of our impella 2.5 product and seeks damages in an unspecified amount . we have moved to dismiss the complaint in its entirety , and that motion has been briefed , argued and is under advisement by the court . separately , on january 21 , 2013 and february 5 , 2013 , we received demands from purported stockholders to inspect certain of our books and records related to these matters . in november 2012 , we announced that the impella rp received investigational device exemption , or ide , approval from the fda for use in a pivotal clinical study in the u.s. the impella rp is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute and is intended to provide the flow and pressure needed to compensate for right side heart failure . during the fourth quarter of fiscal 2013 , we announced the enrollment of the first patient in recover right , an investigational device exemption ( ide ) study of impella rp ( right peripheral ) . we are also conducting initial patient use trials of the impella rp outside of the u.s. this product is not currently available for commercial use . our revenues are primarily generated from our impella line of products . revenues from our non-impella products , largely focused on the heart surgery suite , have been lower recently as we have strategically shifted our sales and marketing efforts towards our impella products and the cath lab . we expect revenues from our non-impella products , including bvs and ab5000 , will continue to decrease as we continue to focus on our impella products . for the year ended march 31 , 2013 , we recognized net income of $ 15.0 million . with the exception of fiscal 2012 and 2013 , we have incurred net losses since our inception . even though we were profitable in fiscal 2013 , we may incur additional losses in the future as we continue to invest in research and development related to our products , conduct clinical studies and registries on our products , expand our commercial infrastructure , pay additional excise taxes as a result of the implementation of the medical device tax in the u.s. in january 2013 , incur additional legal fees to comply with the subpoena received from the department of justice in october 2012 , defend ourselves from other legal claims and invest in new markets such as japan . critical accounting policies and estimates significant estimates our discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements . story_separator_special_tag and defend ourselves from other legal claims and invest in new markets such as japan . fiscal years ended march 31 , 2012 and march 31 , 2011 ( fiscal 2012 and fiscal 2011 ) revenue our revenues are comprised of the following : replace_table_token_7_th total revenues for fiscal 2012 increased by $ 25.2 million , or 25 % , to $ 126.4 million from $ 101.2 million for fiscal 2011. the increase in total revenue was primarily due to higher impella revenue due to greater utilization in the u.s. impella product revenues for fiscal 2012 increased by $ 28.7 million , or 37 % , to $ 106.9 million from $ 78.2 million for fiscal 2011. most of our impella revenue was from disposable product sales of impella 2.5 in the u.s. , as we focused on controlled rollouts for new sites and increasing utilization of these products through continued investment in our sales force and physician training . other product revenues for fiscal 2012 decreased by $ 4.7 million or 30 % , to $ 11.1 million from $ 15.8 million for fiscal 2011. the decrease in other revenue was due to a decline in bvs and ab5000 disposable sales . service and other revenue for fiscal 2012 increased by $ 1.4 million , or 24 % , to $ 7.3 million from $ 5.9 million for fiscal 2011. the increase in service revenue was primarily due to an increase in service contracts , primarily for impella consoles . cost of product revenue cost of product revenue for fiscal 2012 increased by $ 2.5 million or 12 % , to $ 24.5 million from $ 22.0 million for fiscal 2011. gross margin for fiscal 2012 was 81 % compared to 78 % for fiscal 2011. the increase in gross margin was primarily due to higher reorders of impella product disposable pumps and improved manufacturing efficiency . research and development expenses research and development expenses for fiscal 2012 increased by $ 0.5 million , or 2 % , to $ 27.2 million from $ 26.7 million in fiscal 2011. the increase in research and development expenses was due to an increase in spending on product development initiatives associated with 35 impella rp , impella cvad and symphony , and was partially offset by a decrease in clinical trial expenditures as we completed our work associated with the protect ii trial for the impella 2.5. research and development expenses for fiscal 2012 and 2011 included $ 4.9 million and $ 8.8 million , respectively , in clinical trial costs primarily associated with our impella 2.5 u.s. trials . selling , general and administrative expenses selling , general and administrative expenses for fiscal 2012 increased by $ 9.4 million , or 15 % , to $ 71.7 million from $ 62.3 million in fiscal 2011. the increase in selling , general and administrative expenses was primarily due to an increased field headcount as we concentrated our commercial efforts in the u.s. and increased spending on marketing initiatives as we continued to educate physicians on the benefits of hemodynamic support . amortization of intangibles amortization of intangible assets for fiscal 2012 decreased by $ 0.1 million , or 6 % , to $ 1.5 million from $ 1.4 million for fiscal 2011. amortization primarily relates to specifically identified assets from the impella acquisition . gain on sale of worldheart stock in december 2007 , we made a $ 5.0 million investment in worldheart , a developer of an implantable mechanical circulatory support system for chronic heart failure patients . we recorded an impairment charge of $ 5.0 million in fiscal 2008 , reducing the carrying value of the investment to zero . in july 2008 , the note receivable and warrant were converted into common stock of worldheart . in fiscal 2010 we sold 2,543,496 shares of worldheart common stock , which resulted in a gain of $ 6.4 million . in fiscal 2011 we sold our remaining 188,170 shares of worldheart common stock , which resulted in a gain of $ 0.5 million . gain on settlement of investment in december 2011 , we received $ 1.0 million in proceeds in conjunction with a settlement agreement on an investment . income tax provision during fiscal 2012 and 2011 , we recorded a provision for income taxes of $ 1.0 million and $ 0.9 million , respectively . the income tax provision is primarily due to income taxes in germany that we do not expect will be offset by our net operating loss carryforwards in germany and therefore we expect to have a tax liability that we will pay in cash . we have also recorded provisions for income taxes related to our deferred tax liability on our goodwill and alternative minimum tax in the u.s. net income ( loss ) during fiscal 2012 , we incurred net income of $ 1.5 million , or $ 0.04 per basic and diluted share compared to a net loss of $ 11.8 million , or $ 0.32 per share , for the prior fiscal year . the increase in the net income in fiscal 2012 compared to the net loss in fiscal 2011 was due primarily to increased impella sales due to greater demand in the u.s. story_separator_special_tag size= `` 1 `` style= `` font-family : times new roman `` > our operating lease for our facility in danvers , massachusetts expires on february 28 , 2016. monthly rent is as follows : the base rent for november 2008 through june 2010 was $ 40,000 per month ; the base rent for july 2010 through february 2014 is $ 64,350 per month ; and the base rent for march 2014 through february 2016 will be $ 66,000 per month . in addition , we have certain rights to terminate the lease early , subject to the payment of a specified termination fee based on the timing of the termination , as further outlined in

liquidity and capital resources at march 31 , 2013 , our cash , cash equivalents , and short and long-term marketable securities totaled $ 88.1 million , an increase of $ 10.9 million compared to $ 77.2 million in cash , cash equivalents and short-term marketable securities at march 31 , 2012. we believe that our revenue from product sales together with existing resources will be sufficient to fund our operations for at least the next twelve months , exclusive of activities involving any future acquisitions of products or companies that complement or augment our existing line of products . our primary liquidity requirements are to fund the expansion of our commercial infrastructure in the u.s. , increase our impella manufacturing capacity , increase our inventory levels in order to meet increasing customer demand for impella in the u.s. , fund new product development , pay for fees related to the department of justice investigation , our defense of purported class actions and a derivative action , and our response to information requests and provide for general working capital needs . through march 31 , 2013 , we have funded our operations principally from product sales and through the sale of equity securities . we also generate cash through funded research and development revenue . in november 2012 , our board of directors authorized a stock repurchase program for up to $ 15.0 million of our common stock . we financed the stock repurchase program with our available cash . during the year ended march 31 , 2013 , we repurchased 1,123,587 shares for 36 $ 15.0 million in open market purchases at an average cost of $ 13.39 per share , including commission expense . we completed the purchase of common stock under this stock repurchase program in january 2013. marketable securities at march 31 , 2013 consisted of $ 78.7 million held in funds that invest in u.s. treasury and government-backed securities . we are not a party to any interest rate swaps , currency hedges or derivative contracts of any type and have no exposure to commercial paper or auction rate securities markets .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources at march 31 , 2013 , our cash , cash equivalents , and short and long-term marketable securities totaled $ 88.1 million , an increase of $ 10.9 million compared to $ 77.2 million in cash , cash equivalents and short-term marketable securities at march 31 , 2012. we believe that our revenue from product sales together with existing resources will be sufficient to fund our operations for at least the next twelve months , exclusive of activities involving any future acquisitions of products or companies that complement or augment our existing line of products . our primary liquidity requirements are to fund the expansion of our commercial infrastructure in the u.s. , increase our impella manufacturing capacity , increase our inventory levels in order to meet increasing customer demand for impella in the u.s. , fund new product development , pay for fees related to the department of justice investigation , our defense of purported class actions and a derivative action , and our response to information requests and provide for general working capital needs . through march 31 , 2013 , we have funded our operations principally from product sales and through the sale of equity securities . we also generate cash through funded research and development revenue . in november 2012 , our board of directors authorized a stock repurchase program for up to $ 15.0 million of our common stock . we financed the stock repurchase program with our available cash . during the year ended march 31 , 2013 , we repurchased 1,123,587 shares for 36 $ 15.0 million in open market purchases at an average cost of $ 13.39 per share , including commission expense . we completed the purchase of common stock under this stock repurchase program in january 2013. marketable securities at march 31 , 2013 consisted of $ 78.7 million held in funds that invest in u.s. treasury and government-backed securities . we are not a party to any interest rate swaps , currency hedges or derivative contracts of any type and have no exposure to commercial paper or auction rate securities markets .
```    
 Suspicious Activity Report : the panel 's recommendation of class iii for this category of device is consistent with the current class iii designation for these device types . if the fda accepts the panel 's determination and issues a final order classifying these devices in class iii , we will be required to file a pma application for impella 2.5. under the 515 program initiative , we will be permitted to continue to market our impella products pursuant to the 510 ( k ) clearance for a sufficient period of time to allow for the submission and review of pma applications relating to our impella products . we intend to submit a modular pma submission for impella by the end of fiscal 2014. a modular pma allows for a parallel submission of preclinical and manufacturing data for review while still preparing the clinical module . we are working with the fda to prepare this modular pma application for our impella products . in november 2011 , we announced symphony , a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics and potentially improving their quality of life . the device is designed with the primary goal of stabilizing the progression of heart failure and recovering or remodeling the heart . we are currently conducting first-in-human clinical trials of symphony outside the u.s. this product is not currently approved by the fda for sale in the u.s. on october 26 , 2012 , we were informed that the united states attorney 's office for the district of columbia is conducting an investigation that is focused on the company 's marketing and labeling of the impella 2.5. on october 31 , 2012 , we accepted service of a subpoena related to this investigation . the subpoena seeks documents related to the impella 2.5. we are in the process of responding and we intend to cooperate fully with the subpoena . on november 16 and 19 , 2012 , two purported class action complaints were filed against us and certain of our officers in the u.s. district court for the district of massachusetts by alleged purchasers of our common stock , on behalf of themselves and persons or entities that purchased or acquired our securities between august 5 , 2011 and october 31 , 2012. the complaints allege that the defendants violated the 30 federal securities laws in connection with disclosures related to the fda and the marketing and labeling of our impella 2.5 product and seek damages in an unspecified amount . the court has consolidated these complaints . a consolidated amended complaint was filed by the plaintiffs on may 20 , 2013. additionally , on february 4 , 2013 , an alleged holder of our common stock filed a derivative action on our behalf against each of our directors in the u.s. district court for the district of massachusetts . the complaint alleges that the directors breached their fiduciary duties to us and our stockholders in connection with disclosures related to the fda and the marketing and labeling of our impella 2.5 product and seeks damages in an unspecified amount . we have moved to dismiss the complaint in its entirety , and that motion has been briefed , argued and is under advisement by the court . separately , on january 21 , 2013 and february 5 , 2013 , we received demands from purported stockholders to inspect certain of our books and records related to these matters . in november 2012 , we announced that the impella rp received investigational device exemption , or ide , approval from the fda for use in a pivotal clinical study in the u.s. the impella rp is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute and is intended to provide the flow and pressure needed to compensate for right side heart failure . during the fourth quarter of fiscal 2013 , we announced the enrollment of the first patient in recover right , an investigational device exemption ( ide ) study of impella rp ( right peripheral ) . we are also conducting initial patient use trials of the impella rp outside of the u.s. this product is not currently available for commercial use . our revenues are primarily generated from our impella line of products . revenues from our non-impella products , largely focused on the heart surgery suite , have been lower recently as we have strategically shifted our sales and marketing efforts towards our impella products and the cath lab . we expect revenues from our non-impella products , including bvs and ab5000 , will continue to decrease as we continue to focus on our impella products . for the year ended march 31 , 2013 , we recognized net income of $ 15.0 million . with the exception of fiscal 2012 and 2013 , we have incurred net losses since our inception . even though we were profitable in fiscal 2013 , we may incur additional losses in the future as we continue to invest in research and development related to our products , conduct clinical studies and registries on our products , expand our commercial infrastructure , pay additional excise taxes as a result of the implementation of the medical device tax in the u.s. in january 2013 , incur additional legal fees to comply with the subpoena received from the department of justice in october 2012 , defend ourselves from other legal claims and invest in new markets such as japan . critical accounting policies and estimates significant estimates our discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements . story_separator_special_tag and defend ourselves from other legal claims and invest in new markets such as japan . fiscal years ended march 31 , 2012 and march 31 , 2011 ( fiscal 2012 and fiscal 2011 ) revenue our revenues are comprised of the following : replace_table_token_7_th total revenues for fiscal 2012 increased by $ 25.2 million , or 25 % , to $ 126.4 million from $ 101.2 million for fiscal 2011. the increase in total revenue was primarily due to higher impella revenue due to greater utilization in the u.s. impella product revenues for fiscal 2012 increased by $ 28.7 million , or 37 % , to $ 106.9 million from $ 78.2 million for fiscal 2011. most of our impella revenue was from disposable product sales of impella 2.5 in the u.s. , as we focused on controlled rollouts for new sites and increasing utilization of these products through continued investment in our sales force and physician training . other product revenues for fiscal 2012 decreased by $ 4.7 million or 30 % , to $ 11.1 million from $ 15.8 million for fiscal 2011. the decrease in other revenue was due to a decline in bvs and ab5000 disposable sales . service and other revenue for fiscal 2012 increased by $ 1.4 million , or 24 % , to $ 7.3 million from $ 5.9 million for fiscal 2011. the increase in service revenue was primarily due to an increase in service contracts , primarily for impella consoles . cost of product revenue cost of product revenue for fiscal 2012 increased by $ 2.5 million or 12 % , to $ 24.5 million from $ 22.0 million for fiscal 2011. gross margin for fiscal 2012 was 81 % compared to 78 % for fiscal 2011. the increase in gross margin was primarily due to higher reorders of impella product disposable pumps and improved manufacturing efficiency . research and development expenses research and development expenses for fiscal 2012 increased by $ 0.5 million , or 2 % , to $ 27.2 million from $ 26.7 million in fiscal 2011. the increase in research and development expenses was due to an increase in spending on product development initiatives associated with 35 impella rp , impella cvad and symphony , and was partially offset by a decrease in clinical trial expenditures as we completed our work associated with the protect ii trial for the impella 2.5. research and development expenses for fiscal 2012 and 2011 included $ 4.9 million and $ 8.8 million , respectively , in clinical trial costs primarily associated with our impella 2.5 u.s. trials . selling , general and administrative expenses selling , general and administrative expenses for fiscal 2012 increased by $ 9.4 million , or 15 % , to $ 71.7 million from $ 62.3 million in fiscal 2011. the increase in selling , general and administrative expenses was primarily due to an increased field headcount as we concentrated our commercial efforts in the u.s. and increased spending on marketing initiatives as we continued to educate physicians on the benefits of hemodynamic support . amortization of intangibles amortization of intangible assets for fiscal 2012 decreased by $ 0.1 million , or 6 % , to $ 1.5 million from $ 1.4 million for fiscal 2011. amortization primarily relates to specifically identified assets from the impella acquisition . gain on sale of worldheart stock in december 2007 , we made a $ 5.0 million investment in worldheart , a developer of an implantable mechanical circulatory support system for chronic heart failure patients . we recorded an impairment charge of $ 5.0 million in fiscal 2008 , reducing the carrying value of the investment to zero . in july 2008 , the note receivable and warrant were converted into common stock of worldheart . in fiscal 2010 we sold 2,543,496 shares of worldheart common stock , which resulted in a gain of $ 6.4 million . in fiscal 2011 we sold our remaining 188,170 shares of worldheart common stock , which resulted in a gain of $ 0.5 million . gain on settlement of investment in december 2011 , we received $ 1.0 million in proceeds in conjunction with a settlement agreement on an investment . income tax provision during fiscal 2012 and 2011 , we recorded a provision for income taxes of $ 1.0 million and $ 0.9 million , respectively . the income tax provision is primarily due to income taxes in germany that we do not expect will be offset by our net operating loss carryforwards in germany and therefore we expect to have a tax liability that we will pay in cash . we have also recorded provisions for income taxes related to our deferred tax liability on our goodwill and alternative minimum tax in the u.s. net income ( loss ) during fiscal 2012 , we incurred net income of $ 1.5 million , or $ 0.04 per basic and diluted share compared to a net loss of $ 11.8 million , or $ 0.32 per share , for the prior fiscal year . the increase in the net income in fiscal 2012 compared to the net loss in fiscal 2011 was due primarily to increased impella sales due to greater demand in the u.s. story_separator_special_tag size= `` 1 `` style= `` font-family : times new roman `` > our operating lease for our facility in danvers , massachusetts expires on february 28 , 2016. monthly rent is as follows : the base rent for november 2008 through june 2010 was $ 40,000 per month ; the base rent for july 2010 through february 2014 is $ 64,350 per month ; and the base rent for march 2014 through february 2016 will be $ 66,000 per month . in addition , we have certain rights to terminate the lease early , subject to the payment of a specified termination fee based on the timing of the termination , as further outlined in

